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ABSTRACT
Objective: To compare intravaginal 5-fluorouracil (5-FU) and placebo for the treatment of cervical
and/or vaginal human papillomavirus (HPV).
Methods: A randomized, placebo-controlled trial was performed. Women with HPV detected
visually or by Papanicolaou (Pap)test and confirmed by colposcopic biopsy were randomized to
receive either intravaginal 5-FU cream or an intravaginal placebo cream. Women with cervical or
vaginal intraepithelial neoplasia were excluded. The primary outcome measure was cytologic re-
gression ofHPV as determined by Pap test screening 4 to 6 months after treatment. The secondary
outcome was cytologic evidence of disease progression at both the 4-6-month and 12-month follow-
up evaluations. Data were analyzed using the Chi square test with significance established at P <
0.05.
Results: A total of forty patients were randomized, and thirty patients had a follow-up Pap test
4 to 6 months after treatment. Of those patients treated with 5-FU, 28% demonstrated regression
of HPV on cytologic evaluation, compared with 69% of those treated with placebo (P < 0.05).
Twelve-month follow-up cytology was available from 18 of the study participants. There were no
significant differences in the frequency of cytologic progression or regression between groups at 12
months.
Conclusion: Four to six months post treatment, the use of intravaginal 5-FU for the treatment of
cervical or vaginalHPV is associated with a lower rate ofregression than the use of placebo. Infect.
Dis. Obstet. Gynecol. 7:186-189, 1999. (C) 1999 Wiley-Liss, Inc.
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uman papillomavirus (HPV) is a commonly
occurring, sexually transmitted virus that has
been identified as a cause or cofactor in the devel-
opment of lower genital tract dysplasia and carci-
noma. Most HPV infections are asymptomatic and
are identified through cytologic screening or more
advanced DNA technologies. A smaller percentage
manifest as external or internal genital warts. The
treatment of lower genital tract HPV can be diffi-
cult because the disease tends to be recurrent or
persistent even after lesions are destroyed. 2 Treat-
ment strategies for HPV without evidence of dys-
plasia are controversial, especially for subclinical
disease that is identified through routine cytologic
screening. Although spontaneous regression rates
ofHPV related atypia and dysplasia may be as high
as 76%,3 there is also evidence demonstrating the
progression ofHPV lesions to carcinoma in situ and
invasive cancer.3-5 This malignant potential has
prompted some investigators to recommend treat-
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ment of subclinical HPV to prevent subsequent
carcinogenesis.6
The antimetabolite 5-fluorouracil (5-FU) has
been recommended for the treatment of subclinical
HPV, genital warts,, and lower genital tract .dyspla-
sia.7-9 It has the advantage of being an inexpensive
treatment that does not require special equipment
or anesthesia. However, 5-FU is associated with
significant side effects, including acute vulvovagi-
nitis, chronic epidermal or mucosal erosions, and
acquired adenosis.1-13
Some clinicians prescribe 5-FU for clinical and
subclinical HPV despite the adverse side effect
profile and evidence to suggest that HPV often
undergoes spontaneous regression or resolution. It
is the purpose of this study to evaluate the effec-
tiveness of intravaginal 5-FU cream versus placebo
cream for the treatment of vaginal or cervical HPV.
METHODS
Between February 1996 and March 1997, a ran-
domized, double-blind, placebo-controlled study
was conducted at the Medical University of South
Carolina’s outpatient colposcopy clinic, a referral
center for patients with abnormal cervical cytologic
screening results. The protocol was approved by
the institutional review board, and all patients gave
written informed consent before inclusion in the
study. Subjects eligible for inclusion were females
between the ages of 18 and 45 years who had a
screening Pap test demonstrating abnormalities
consistent with HPV and also had colposcopic-
directed biopsies confirming HPV. Patients with a
colposcopic biopsy revealing cervical intraepithelial
neoplasia (CIN) were excluded from participation.
Additionally, only those patients using some form
of barrier, hormonal, or surgical contraception were
included. Other exclusion criteria included preg-
nancy, known hypersensitivity to 5-FU, known hu-
man immunodeficiency virus, and clinical evidence
of vaginitis or cervicitis.
Patients who met the inclusion criteria were ran-
domized in a 1:1 ratio to receive either intravaginal
5-FU or placebo. The research pharmacist gener-
ated the randomization list using a computer-
generated randomization table. The 5-FU cream
used was a marketed 5% cream preparation (Efu-
dex, Roche Laboratories, Basel, Switzerland). The
placebo cream was compounded by the research
pharmacist using a similar cream base which made
the two preparations indistinguishable by sight or
smell. The treatment and placebo creams were dis-
pensed in prefilled intravaginal applicators, and the
appropriate quantity of applicators for the entire
treatment protocol was placed in a single envelope.
The envelopes were numbered sequentially ac-
cording to the randomization list. Subjects were
instructed by study nursing personnel in the tech-
nique for medication application. Intravaginal ap-
plications were administered weekly for 4 weeks,
then every other week for two additional doses.
This dosing regimen has been reported by previous
authors. 7 The dosing schedule was reinforced with
a treatment calendar on which days of treatment
were circled. Compliance with treatment was
monitored by having each subject mark her treat-
ment calendar the day she used the medication.
Repeat cytologic assessment by Pap test was per-
formed within 4-6 months after randomization and
recorded for analysis. Subsequent follow-up Pap
test results were recorded for up to 18 months after
enrollment.
The primary outcome measure was the fre-
quency of cytologic regression of HPV as deter-
mined by Pap test screening 4 to 6 months after
randomization. Secondary outcomes included any
cytologic evidence of progression of disease; this
was calculated for the 4-6- month follow-up inter-
val and also for the 12-18-month follow-up inter-
val. Data were analyzed using the Chi square test
with significance established at P < 0.05.
RESULTS
Forty patients were randomized to receive either
intravaginal 5-FU or placebo. Thirty patients (5-
FU 14, placebo 16 presented for follow-up
cytologic evaluation between 4 and 6 months after
initiation of intravaginal therapy. Of those patients
treated with 5-FU, 28% demonstrated regression of
HPV on cytologic evaluation, compared with 69%
of those treated with placebo (P < 0.05). Addition-
ally, 64% of those patients treated with 5-FU had
cytologic evidence of progressive dysplasia, com-
pared with 31% of those exposed to placebo only (P
0.07). No patients in either group demonstrated
cytologic progression beyond mild dysplasia (CIN
I) on the initial 4-6-month follow-up Pap test.
Twelve-month follow-up cytology was available
for 18 of the study participants (5-FU 10, placebo
8 ). There were no significant differences in the
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frequency of cytologic progression or regression be-
tween groups. Only five of the 18 demonstrated
cytologic abnormalities, none of which progressed
beyond mild dysplasia.
DISCUSSION
Our randomized, controlled trial of intravaginal
5-FU versus placebo for the treatment of subclini-
cal vaginal or cervical HPV indicates that 4 to 6
months after treatment, patients using placebo
demonstrate regression of HPV more frequently
than those treated with 5-FU. One year out from
treatment, there seems to be no difference be-
tween treatment groups with respect to disease
progression or regression. Our findings do not sup-
port the high response rate identified by Krebs in
his study of 5-FU for the treatment of vaginal con-
dyloma. 7 In his series of 20 patients, a similar dos-
ing regimen of 5-FU was prescribed, and 85% of
patients had no evidence of disease by colposcopy
and cytology at 3 months posttreatment; there were
no control patients in this study for comparison. In
a comparative treatment study for condyloma acu-
minata, Ferenczy found 5-FU to be more effective
than COz laser ablation for the treatment of con-
dyloma acuminata. 13 Based on these previous stud-
ies, our findings of poorer outcomes among the
5-FU users was unexpected.
The less desirable outcome associated with
5-FU treatment in our study may even suggest an
adverse effect of 5-FU on subclinical HPV. Per-
haps the antimetabolite action of 5-FU transiently
interrupts the normal immune function that is re-
sponsible for spontaneous regression. Another
study using 5-FU or trichloroacetic acid (TCA) as a
"prophylactic" treatment following laser ablation of
subclinical cervicovaginal HPV demonstrated a
similar "worsening" of HPV among subjects
treated with 5-FU, but not among those who were
treated with nothing or with trichloroacetic acid. 14
In this observational study, the group treated with
laser plus 5-FU had recurrence/persistence rates of
68% at 3 months compared with the control group
(laser treatment only) with 19% and the laser-plus-
TCA group with 15%. In our study, 69% of the
placebo users had regression of the disease at the
4-6-month follow-up visit. This is consistent with
the high spontaneous regression rates reported by
others.3, 15
Our data on longer term outcomes are severely
limited by poor follow-up compliance among our
study subjects. Of the original 40 patients who
were randomized, only 18 returned during the 12-
18-month follow-up interval. Five of the 18 pa-
tients screened at 12-18 months had either persis-
tent HPV or mild dysplasia; the remainder had nor-
mal cytology. Although there was no difference
between the treatment and placebo groups, we
cannot make any conclusions based on this small
number.
We had no reports of serious side effects other
than minor vulvar irritation reported by one pa-
tient. The remainder of patients who returned for
the first follow-up visit reported and documented
compliance with the study treatment protocol We
do not believe that the poor follow-up rates are
related to treatment compliance or adverse side ef-
fects, but are more likely the result of serving a
largely indigent, referral population.
In conclusion, our study demonstrates that the
use of 5-FU for the treatment ofHPV infections of
the cervix and vagina is associated with a lower rate
of regression than the use of placebo. Given this
lack of efficacy and data supporting the high rate of
spontaneous resolution of HPV, it is appropriate to
follow these patients with regular cytologic screen-
ing and avoid the use of caustic therapy that may
indeed have an undesirable effect on subclinical
disease.
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